Default company panoramic image
93747336 1489 4003 9e8a a7dbaaa34d64

Cohen Medical

COHENMedical is a specialty drug delivery company with a perivascular platform developing IP.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location New York City, NY, USA
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Website

Company Summary

COHENMedical, a specialty drug delivery company with a perivascular platform, focusing on unmet medical needs. An example of this application is the growing epidemic of Peripheral Arterial Disease (PAD) and its consequent severe manifestations: intermittent claudication (IC) and critical limb ischemia (CLI).


  • Default avatar
    Dan H Kim

    Mr. Kim has over 25 years' experience in global pharmaceutical commercialization. His therapeutic
    experience includes infectious diseases, oncology and hospital medical devices ranging from wound care
    to aesthetic products. He has worked with senior executives and scientists at Roche, Pfizer and Novartis,
    developing a unique strategic approach to therapeutic franchise development with over $1B in investment.
    He has led commercial and scientif

  • Default avatar
    Joe Farzetta

    Mr. Farzetta has a broad and extensive career of over thirty years in the pharmaceutical industry
    including tenure with major pharmaceutical companies Novartis, Fisons (now UCB) and Alpharma. He
    is experienced in multiple dosage forms, drug delivery technologies and commercial operations. This
    product and market knowledge is coupled with a broad based knowledge of commercial development that
    includes numerous transactions including product ac

  • Default avatar
    Ilsoon Yang

    Ilsoon Yang brings a breadth of analytical and strategic expertise to COHENMedical, with past
    experiences in the financial services and pharmaceutical industries. She has demonstrated success in
    business strategy development and risk management through profit and loss forecast, portfolio
    performance analysis, test development and analysis, and segmentation development to optimize risk and
    return trade-offs.
    Previous to her most recent role a

  • Default avatar
    David Cohen

    Dr. Cohen received his Bachelor and Master of Science d e g r e e s from the City University of New York and
    his Ph.D. from the University of Massachusetts School of Medicine. He did his postdoctoral fellowship at
    Ciba-Geigy Corporation, Summit, NJ and Horsham, UK. Dr. Cohen spent nearly 20 years in cardiovascular
    drug discovery research as a Principal and Distinguished Fellow. He led groups that were instrumental in the
    development of five m


  • Default avatar
    Henry Park